Dopamine D₂ receptor modulation of human response inhibition and error awareness

Nandam, L. Sanjay, Hester, Robert, Wagner, Joe, Dean, Angela J., Messer, Cassandra, Honeysett, Asha, Nathan, Pradeep J. and Bellgrove, Mark A. (2013) Dopamine D₂ receptor modulation of human response inhibition and error awareness. Journal of Cognitive Neuroscience, 25 4: 649-656. doi:10.1162/jocn_a_00327

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Nandam, L. Sanjay
Hester, Robert
Wagner, Joe
Dean, Angela J.
Messer, Cassandra
Honeysett, Asha
Nathan, Pradeep J.
Bellgrove, Mark A.
Title Dopamine D₂ receptor modulation of human response inhibition and error awareness
Journal name Journal of Cognitive Neuroscience   Check publisher's open access policy
ISSN 0898-929X
Publication date 2013
Sub-type Article (original research)
DOI 10.1162/jocn_a_00327
Open Access Status File (Publisher version)
Volume 25
Issue 4
Start page 649
End page 656
Total pages 8
Place of publication Cambridge, MA, United States
Publisher M I T Press
Collection year 2014
Language eng
Abstract Response inhibition, comprising action cancellation and action restraint, and error awareness are executive functions of considerable clinical relevance to neuropsychiatric disorders. Nevertheless, our understanding of their underlying catecholamine mechanisms, particularly regarding dopamine, is limited. Here, we used the dopamine D2 agonist cabergoline to study its ability to improve inhibitory control and modulate awareness of performance errors. A randomized, double-blind, placebo-controlled, crossover design with a single dose of cabergoline (1.25 mg) and placebo (dextrose) was employed in 25 healthy participants. They each performed the stop-signal task, a well-validated measure of action cancellation, and the Error Awareness Task, a go/no-go measure of action restraint and error awareness, under each drug condition. Cabergoline was able to selectively reduce stop-signal RT, compared with placebo, indicative of enhanced action cancellation (p <.05). This enhancement occurred without concomitant changes in overall response speed or RT variability and was not seen for errors of commission on the Error Awareness Task. Awareness of performance errors on the go/no-go task was, however, significantly improved by cabergoline compared with placebo (p <.05). Our results contribute to growing evidence for the dopaminergic control of distinct aspects of human executive ability, namely, action cancellation and error awareness. The findings may aid the development of new, or the repurposing of existing, pharmacotherapy that targets the cognitive dysfunction of psychiatric and neurological disorders. They also provide further evidence that specific cognitive paradigms have correspondingly specific neurochemical bases.
Keyword Neuropsychiatric disorders
Error awareness
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 21 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 25 Feb 2013, 13:03:34 EST by Debra McMurtrie on behalf of Queensland Brain Institute